Skip to main content

CombiMatrix Taps New SAB Member; Bell Leaves Genetix Board; Affy VP Becomes Nanomix Director; Sequenom Fleshes Out Genetic Analysis Arm; and Others

Jonathan Said has joined CombiMatrix's wholly owned subsidiary, CombiMatrix Molecular Diagnostics, as a member of its Scientific Advisory Board, the Acacia Research Corporation said today.


On the board, he will provide knowledge in the area of lymphoma molecular pathology.


Said is a board certified anatomic pathologist and is chief of the Division of Anatomic Pathology and chief of Surgical Pathology at the Department of Pathology and Laboratory Medicine at California's UCLA Medical Center for the Health Sciences.


He received his medical degree from the University of Witwatersrand Medical School, Johannesburg, South Africa and completed his pathology residencies at the Mallory Institute of Pathology and Peter Bent Brigham Hospital, Boston, Massachusetts. He completed clinical and research pathology fellowships at Harvard Medical School.

Gregory T. Schiffman, Affymetrix's executive vice-president and chief financial officer, joined Nanomix's board of directors, Nanomix said yesterday. He will chair the audit committee.


Schiffman has been with Affymetrix since 2001 when he left Applied Biosystems and has over 25 years of experience in finance, manufacturing, and distribution management.

Sequenom announced yesterday three hires for its genetics analysis service business that was launched in October 2005.


Jeffrey Otto joined Sequenom as director, Min Seob Lee as manager, and Donald Benson as national account manager.


Prior to Sequenom, Otto held numerous positions at Genaissance Pharmaceuticals from 2000 to 2005. From 1995 to 2000, Otto completed his post-doc fellowship and was principal investigator in the department of orthopedic surgery molecular biology and genetics laboratory at Rush-Presbyterian Department of Orthopedic Surgery-St. Luke's Medical Center.


Lee conducted his post-doctoral fellowship at Harvard Medical School, Beth Israel Deaconess Medical Center and received a Ph.D. in biological science from the City of Hope National Medical Center and Beckman Research Institute.


Benson has over 20 years of pharmaceutical and biotechnology sales experience from companies such as Bios, Boehringer Mannheim Biochemicals, Eppendorf North America, Genaissance, Orchid Biosciences, QIAGEN and Protein-DNA Imageware.

As reported in GenomeWeb News yesterday, Guava Technologies promoted chief operating officer Lawrence F. Bruder to chief executive officer and added two vice-presidents to the senior management team.


The new vice-president of commercial operations, Todd P. Christian, comes to Guava from Applied Biosystems and BD Biosciences, where he held various positions, including general manager.


The new vice-president of corporate development and strategic marketing, Lalit Dhir, was a vice-president at BD Biosciences and gained management experience at Pharmingen.

Trevor Bell, Genetix Group's current chief operating officer, will be resigning from the Board of Directors on Jan. 11, 2006, the company said yesterday.


According to Genetix, the departure follows changes to the board which will make the role of a chief operating officer redundant.

Nonlinear Dynamics appointed Martin Wells as international sales manager earlier this week, the company said.


Prior to Nonlinear, Wells spent 13 years in a variety of senior sales and marketing positions at Helena BioSciences.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.